Halozyme Therapeutics Reports 2008 First Quarter Financi...( - Pipeline Update Conference Call an...)

- Pipeline Update Conference Call and Webcast on May 9 at 8:00 a.m. PDT -

SAN DIEGO, May 8 /PRNewswire-FirstCall/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO), a biopharmaceutical company developing and commercializing products targeting the extracellular matrix, today reported financial results for the three months ended March 31, 2008.

"This year is off to a solid start as we significantly advanced both our partnered and proprietary programs in the first quarter of 2008," said Jonathan Lim, MD, Halozyme's President and CEO. "In addition, we are pleased to disclose that insulin is the target of our "Cheetah" program. We will be presenting Phase I clinical data at the upcoming American Diabetes Association meeting next month in San Francisco. This study was designed to identify whether injections of mealtime insulins formulated with PH20 could create a more rapid blood glucose control compared to the best insulin products available today indicated for diabetes. The existing global market for insulin and insulin analogs is estimated at $10 billion. A faster acting insulin may allow physicians and patients tighter glycemic control that more closely mimics natural physiologic human insulin levels and potentially result in a reduction of long-term complications."

Recent Scientific Achievements

-- Preliminary results of a Phase I/II clinical trial demonstrated that

subcutaneous infusion (under the skin) of GAMMAGARD LIQUID [Immune

Globulin Intravenous (Human)] (IGIV) with Enhanze(TM) Technology

enabled administration of a full monthly dose of immune globulin via a

single subcutaneous site to patients with primary immunodeficiency

(PID). Baxter presented the res
'/>"/>